To include your compound in the COVID-19 Resource Center, submit it here.

Kineret anakinra: Phase II/III data; Under review in the U.S., Canada, Europe and Australia

Additional data from AMGN's 472-patient Phase II trial of Kineret showed that 75 mg and 150 mg doses of the

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE